Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : May 21, 2019 09:51 AM IST | Source: PTI

Glenmark Pharma gets USFDA nod for overactive bladder treatment drug

Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg," the company said in a BSE filing.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharmaceuticals has received final approval from the US health regulator for Solifenacin Succinate tablets, used for treatment of overactive bladder. The approved product is a generic version of Vesicare tablets of Astellas Pharma US, Inc.

Glenmark Pharmaceuticals Inc., USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg," the company said in a BSE filing.

Quoting IQVIA sales data for the 12 month period ending March 2019, Glenmark Pharma said the Vesicare tablets, 5 mg and 10 mg market achieved annual sales of approximately USD 942.7 million.

Close

The company's current portfolio consists of 154 products authorised for distribution at the US marketplace and 58 abbreviated new drug applications (ANDAs) pending approval with the USFDA.

Shares of Glenmark Pharma were trading 0.39 per cent higher at Rs 577.91 apiece on BSE.

Subscribe to Moneycontrol Pro and gain access to curated markets data, exclusive trading recommendations, independent equity analysis, actionable investment ideas, nuanced takes on macro, corporate and policy actions, practical insights from market gurus and much more.
First Published on May 21, 2019 09:47 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant